Osiris Therapeutics Revenue

Osiris Therapeutics revenue was $142.82 m in FY, 2018

Embed Graph

Summary - Funding Rounds

Founding Date

1992

Total Funding

$65 m

Investors

In total, Osiris Therapeutics had raised $65 m. Osiris Therapeutics is a subsidiary of Smith & Nephew

Osiris Therapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2017FY, 2018

Revenue

41.1m7.8m24.3m59.9m118.5m142.8m

Cost of goods sold

531.0k2.6m6.7m13.2m32.7m38.1m

Gross profit

40.6m5.3m17.7m46.7m85.8m104.7m

Gross profit Margin, %

99%67%73%78%72%73%

Sales and marketing expense

61.5m67.5m

R&D expense

19.2m14.1m5.0m6.9m4.1m6.8m

General and administrative expense

5.9m6.1m15.3m37.4m22.1m19.6m

Operating expense total

(14.1m)16.4m20.5m45.0m87.8m94.8m

EBIT

14.8m(11.2m)(2.8m)1.7m(2.0m)9.9m

EBIT margin, %

36%(142%)(12%)3%(2%)7%

Interest income

49.0k414.0k

Pre tax profit

14.9m(11.1m)(2.4m)(53.0k)(2.6m)10.5m

Income tax expense

43.0k(37.0k)(1.3m)193.0k(1.4m)(26.0m)

Net Income

14.9m(11.1m)41.6m(1.8m)8.8m36.9m

Osiris Therapeutics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2017FY, 2018

Cash

1.7m1.9m2.4m2.2m3.1m16.4m

Accounts Receivable

728.0k3.1m7.5m24.3m26.1m22.5m

Prepaid Expenses

470.0k603.0k355.0k650.0k2.9m3.5m

Inventories

767.0k1.3m1.9m10.9m11.3m9.6m

Current Assets

51.4m39.0m84.1m95.9m72.9m70.2m

PP&E

2.5m2.1m1.9m2.1m3.6m2.9m

Total Assets

54.3m41.5m92.1m98.1m78.1m101.5m

Accounts Payable

4.7m5.0m4.8m8.9m5.3m4.1m

Short-term debt

44.0k45.0k45.0k

Current Liabilities

8.0m5.0m10.8m10.6m35.1m20.6m

Long-term debt

162.0k117.0k72.0k

Total Debt

206.0k

Total Liabilities

8.5m5.6m11.1m14.2m36.7m23.0m

Common Stock

33.0k33.0k34.0k35.0k35.0k35.0k

Additional Paid-in Capital

278.1m279.3m282.7m287.5m283.9m284.2m

Retained Earnings

(232.3m)(243.4m)(201.8m)(203.5m)(242.3m)(205.4m)

Total Equity

45.8m35.9m80.9m84.0m41.4m78.5m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.2 x1.2 x1.1 x1.2 x1.9 x1.3 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2018Q2, 2018Q3, 2018

Cash

1.5m1.4m1.6m1.1m1.1m1.3m1.6m1.8m2.3m2.7m946.0k3.7m1.6m15.8m3.4m23.1m31.7m

Accounts Receivable

1.6m1.5m997.0k1.4m2.2m5.3m6.4m6.8m11.8m16.9m21.4m32.0m38.6m37.9m26.5m23.5m20.6m

Prepaid Expenses

743.0k762.0k636.0k3.4m1.1m462.0k356.0k639.0k318.0k404.0k489.0k579.0k1.2m1.2m3.1m2.9m3.4m

Inventories

623.0k729.0k415.0k475.0k922.0k1.6m1.7m1.7m2.3m5.5m8.8m11.9m13.3m15.8m11.0m11.1m10.6m

Current Assets

61.4m57.0m47.4m44.0m41.4m37.0m35.7m37.6m83.5m87.1m89.6m99.4m100.8m98.7m73.3m74.7m79.7m

PP&E

2.8m2.6m2.3m2.2m2.2m2.0m2.0m2.0m1.8m1.9m2.0m2.2m2.1m2.2m3.5m3.3m3.1m

Total Assets

64.7m60.1m50.1m46.5m44.0m39.4m38.0m39.8m91.3m89.2m91.7m101.6m103.0m101.0m78.6m79.8m84.7m

Accounts Payable

4.4m5.6m4.8m5.2m5.0m5.0m4.0m8.0m9.3m9.8m9.2m9.6m5.8m5.5m4.3m

Dividends Payable

6.9m

Short-term debt

44.0k44.0k45.0k45.0k45.0k45.0k45.0k45.0k45.0k45.0k

Current Liabilities

28.2m19.2m4.8m5.2m5.0m5.0m6.9m7.7m9.8m8.1m9.3m11.5m10.9m18.2m37.1m35.7m36.4m

Long-term debt

173.0k151.0k140.0k128.0k

Total Debt

217.0k195.0k185.0k128.0k45.0k45.0k45.0k45.0k45.0k45.0k

Total Liabilities

28.7m19.6m5.2m5.6m5.6m5.5m7.3m8.1m10.1m8.4m9.6m15.1m14.2m21.2m39.6m38.1m38.8m

Common Stock

33.0k33.0k33.0k33.0k33.0k33.0k33.0k34.0k34.0k34.0k35.0k35.0k35.0k35.0k35.0k35.0k35.0k

Additional Paid-in Capital

277.4m277.7m278.5m278.8m279.1m279.9m280.6m283.4m284.2m285.7m286.4m288.8m290.0m284.0m284.0m284.0m284.1m

Retained Earnings

(241.4m)(237.4m)(233.6m)(237.9m)(240.8m)(246.1m)(249.9m)(251.6m)(203.1m)(205.0m)(204.4m)(202.2m)(201.0m)(204.1m)(244.7m)(242.2m)(238.0m)

Total Equity

36.1m40.4m44.9m41.0m38.4m33.8m30.7m31.8m81.2m80.8m82.1m86.5m88.8m79.8m38.9m41.7m45.9m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Financial Leverage

1.8 x1.5 x1.1 x1.1 x1.1 x1.2 x1.2 x1.3 x1.1 x1.1 x1.1 x1.2 x1.2 x1.3 x2 x1.9 x1.8 x

Osiris Therapeutics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2017FY, 2018

Net Income

14.9m(11.1m)8.8m36.9m

Depreciation and Amortization

745.0k708.0k587.0k940.0k688.0k873.0k

Accounts Receivable

1.2m(2.4m)(4.7m)(18.0m)(2.8m)3.6m

Inventories

(511.0k)(651.0k)(9.0m)88.0k135.0k

Accounts Payable

(912.0k)246.0k

Cash From Operating Activities

(20.4m)(13.3m)(13.3m)(3.1m)(5.2m)7.3m

Purchases of PP&E

(81.0k)(128.0k)(528.0k)(1.1m)(2.0m)(242.0k)

Cash From Investing Activities

20.5m13.3m11.6m1.1m5.3m6.0m

Cash From Financing Activities

151.0k140.0k2.2m1.9m128.0k7.0k

Net Change in Cash

219.0k193.0k562.0k(208.0k)248.0k13.3m

Income Taxes Paid

539.0k619.0k134.0k

Osiris Therapeutics Ratios

USDQ2, 2011

Financial Leverage

1.8 x

Osiris Therapeutics Employee Rating

2.431 votes
Culture & Values
2.2
Work/Life Balance
2
Senior Management
2
Salary & Benefits
2.9
Career Opportunities
2.6
Source